This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-28 and is reviewed periodically as new material appears.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
=== 2003 === 15 March Space Shuttle: Human Time Bomb? about STS-107, which broke up on 1 February 2003; Bill Readdy of NASA; technology writer Dwayne A. Day; the shuttle engines burned 1.5 tonnes per second; physicist Ted Postol of MIT; Vladimir Titov and Gennady Strekalov deployed a launch escape system on Soyuz 7K-ST No.16L on 26 September 1983; the shuttle design was hampered by a need for a large-enough payload bay, to take 60-ft spy satellites for the USAF, and the shuttle's original companion launch vehicle (similar to the North American DC-3) was exchanged for a disposable fuel tank; in May 1995 for STS-70, woodpeckers destroyed a large part of the foam coating on the fuel tank next to Discovery on the launch pad - NASA bought six lifesize owls from a nearby supermarket to frighten the woodpeckers away; on 7 October 2002 on the launch of STS-112, foam broke away from the fuel tank, causing damage, which NASA ignored; Jeff Hoffmann; on 1 February 2003 at around 8am Nacogdoches, Texas was hit by debris. Narrated by Heather Couper, produced by Stuart Carter, directed by Alex Hearle, made by Pioneer Productions. Filmed, edited and broadcast only twenty three days after being commissioned Self-Experimenters, about self-experimentation in medicine; neuroscientist Simon Gandevia from the Prince of Wales Medical Research Institute (since 2010, Neuroscience Research Australia); Canadian thermophysiologist Gordon Giesbrecht at the University of Manitoba in Winnipeg; medicinal chemist and psychopharmacologist Sasha Shulgin; medicinal chemist David E.
== Metabolite Quantification and Analysis == In order to identify and quantify metabolites produced by the body, various detection methods have been employed. Most often, these involve the use of nuclear magnetic resonance (NMR) spectroscopy or mass spectrometry (MS), providing universal detection, identification and quantification of metabolites in individual patient samples. Although both processes are used in pharmacometabolomic analyses, there are advantages and disadvantages for using either nuclear magnetic resonance (NMR) spectroscopy- or mass spectrometry (MS)-based platforms in this application.
The antiandrogenic activity of CPA is dose-dependent. Although CPA is a potent antiandrogen, relatively high doses of CPA are nonetheless required for clinically important AR antagonism. The clinical antiandrogenic efficacy of birth control pills containing CPA, which have only low doses of CPA in them (2 mg/day), often can't be distinguished from that of birth control pills containing other progestins. It is likely that the antiandrogenic effects of CPA-containing birth control pills are due mostly to the ethinylestradiol component and/or suppression of androgen levels, rather than the antiandrogenic activity of the small doses of CPA present in them. CPA has been found to decrease inflammatory acne lesions in males by about 15% at 5 mg/day, by 45% at 25 mg/day, and by 73% at 100 mg/day. A dosage of 100 mg/day CPA can achieve a 65 to 70% reduction in sebum excretion rate in males within 4 weeks of treatment, but doses of 10 mg/day CPA or less are said to have a negligible effect. On the basis of these findings, it has estimated that the threshold dosage of CPA to reduce sebum production may be 5 mg/day in males. In other studies, 25 mg/day CPA resulted in substantial improvement or complete clearance of severe acne in almost all males, whereas 12.5 mg/day was ineffective. CPA has been found to be strongly catabolic in young healthy males. It was shown to result in a mean negative nitrogen balance of 1.2 g at 50 mg/day, 1.4 g at 100 mg/day, and 2.5 g at 200 mg/day. This corresponded to mean losses of lean tissue of 780, 945, and 1,515 g, respectively.
=== Early career === In 1966, Jim and Tammy Faye Bakker began working at Pat Robertson's Christian Broadcasting Network (CBN) in Portsmouth, Virginia, which had an audience in the low thousands at the time. The Bakkers contributed to the network's growth, hosting a children's variety show called Come On Over that employed comic routines with puppets. Due to the success of Come On Over, Robertson made Bakker the host of a new prime-time talk show, The 700 Club, which gradually became CBN's flagship program. The Bakkers left CBN in 1973 and, soon after, joined with Paul and Jan Crouch to help co-found the Trinity Broadcasting Network (TBN) in California. However, this partnership lasted only eight months until a falling-out between Jim Bakker and Paul Crouch caused the Bakkers to eventually leave the new network.
==== Output ==== After an incident particle has fused with a parent nucleus, if the excitation energy is sufficient, the nucleus breaks into fragments. This is called scission, and occurs at about 10−20 seconds. The fragments can emit prompt neutrons at between 10−18 and 10−15 seconds. At about 10−11 seconds, the fragments can emit gamma rays. At 10−3 seconds β decay, β-delayed neutrons, and gamma rays are emitted from the decay products. Typical fission events release about two hundred million eV (200 MeV) of energy for each fission event. The exact isotope which is fissioned, and whether or not it is fissionable or fissile, has only a small impact on the amount of energy released. This can be easily seen by examining the curve of binding energy (image below), and noting that the average binding energy of the actinide nuclides beginning with uranium is around 7.6 MeV per nucleon. Looking further left on the curve of binding energy, where the fission products cluster, it is easily observed that the binding energy of the fission products tends to center around 8.5 MeV per nucleon. Thus, in any fission event of an isotope in the actinide mass range, roughly 0.9 MeV are released per nucleon of the starting element. The fission of 235U by a slow neutron yields nearly identical energy to the fission of 238U by a fast neutron. This energy release profile holds for thorium and the various minor actinides as well.
Sources: en.wikipedia.org
=== Stress === Chronic stress can aggravate allergic conditions. This has been attributed to a T helper 2 (TH2)-predominant response driven by suppression of interleukin 12 by both the autonomic nervous system and the hypothalamic–pituitary–adrenal axis. Stress management in highly susceptible individuals may improve symptoms.
== Types of decay == The four most common modes of radioactive decay are: alpha decay, beta decay, inverse beta decay (considered as both positron emission and electron capture), and isomeric transition. Of these decay processes, only alpha decay (fission of a helium-4 nucleus) changes the atomic mass number (A) of the nucleus, and always decreases it by four. Because of this, almost any decay will result in a nucleus whose atomic mass number has the same residue mod 4. This divides the list of nuclides into four classes, each of which forms a main decay chain. Three of these are readily observed in nature, commonly called the thorium series, the radium or uranium series, and the actinium series, representing three of these four classes, and ending in three different, stable isotopes of lead. The mass number of every isotope in the chain can be represented as A = 4n, A = 4n + 2, or A = 4n + 3, respectively. The long-lived starting isotopes of these three isotopes, respectively thorium-232, uranium-238, and uranium-235, have existed since the formation of the Earth, ignoring the artificial isotopes and their decays created since the 1940s. Due to the relatively short half-life of its starting isotope neptunium-237 (2.144 million years), the fourth chain, the neptunium series with A = 4n + 1, is already extinct in nature, except for the final rate-limiting step, decay of bismuth-209. Traces of 237Np and its decay products do occur in nature, however, as a result of neutron reactions in uranium ore; neutron capture by natural thorium to give 233U is also possible.
== Medical uses == Relugolix is approved in the United States, Canada and the United Kingdom for the treatment of prostate cancer, in Japan for the treatment of uterine fibroids (uterine leiomyoma) and in the United Kingdom for endometriosis.
Neither of these ocular signs should be confused with exophthalmos (protrusion of the eyeball), which occurs specifically and uniquely in hyperthyroidism caused by Graves' disease (note that not all exophthalmos is caused by Graves' disease, but when present with hyperthyroidism is diagnostic of Graves' disease). This forward protrusion of the eyes is due to immune-mediated inflammation in the retro-orbital (eye socket) fat. Exophthalmos, when present, may exacerbate hyperthyroid lid-lag and stare.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.